Citi Downgrades Several Life Science Tools Vendors, Citing End Market Concerns | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Citi Investment Research & Analysis today downgraded a number of life science tools firms saying end market weakness is expected to continue through 2012.

In a research report, analyst Amit Bhalla said the academic/government market will face pressure while pharma/biotech will see headwinds for the next year, limiting growth opportunities for tools vendors.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: a sequencing-based screen of Lyme disease-causing pathogen, the range of animals bitten by Anopheles darling mosquitoes in Peru, and more.

An NC State researcher is exploring the use of CRISPR-Cas3 as an anti-microbial, Gizmodo reports.

The Earth BioGenome Project plans to sequence all life on Earth, according to ScienceInsider.

For those who are concerned about Trump administration actions related to science, a new column in Scientific American has suggestions for ways to fight back.